Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
A study published in The American Journal of Managed Care® (AJMC®) was cited by RevCycle Intelligence. The researchers of the study, “Patients’ Views on Price Shopping and Price Transparency,” interviewed patients with access to a price transparency website and found that despite having a positive opinion of price shopping in theory, patients reported barriers to doing so in reality.
The National Pharmaceutical Council’s Wednesday CER Daily Newsfeed included 2 articles from AJMC® on curative therapies from the “Paying for Cures: Ensuring patient access and system sustainability” event. The article “Preparing Patients and the Health System for Curative Therapies in the Pipeline” covered a session where experts discussed how the healthcare system can pay for curative therapies that have high upfront costs with benefits that accrue over time. The article “Examining New Payment Ideas for Curative Therapies” sought to answer the question of how the health system can ensure that cutting-edge gene therapies and other curative therapies get to the patients that need them without leaving payers financially exposed.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Insurance Coverage Limits JAKi Therapy Access for Patients With AA, Especially Non-White Populations
April 25th 2024A survey study showed major barriers to Janus kinase inhibitor (JAKi) therapy for patients with alopecia areata, especially for non-White patients who face higher rates of being uninsured and struggle more to afford the treatment.
Read More